Daniel Arturo Martínez-Piña

Daniel Arturo Martínez-Piña

Auto-generated profile, based on publicly available information

Daniel Arturo Martínez-Piña

Secretaría de Salud, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Servicio de Neurología. Ciudad de México, México Secretaría de Salud México

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022
Verified
Book Chapter
Open access
PDF file
DMDaniel Arturo Martínez-Piña
Daniel Arturo Martínez-Piña
GAGustavo Alexis Alvarado-Fernández
Gustavo Alexis Alvarado-Fernández
EGEdith González-Guevara
Edith González-Guevara
CCCarlos Castillo-Pérez
Carlos Castillo-Pérez
GRGerardo Romero-Luna
Gerardo Romero-Luna
JTJorge Alejandro Torres-Ríos
Jorge Alejandro Torres-Ríos
Glucose provides the necessary fuel to cover the physiological functions of the organism. In the brain, glucose represents the main energy supply through the generation of adenosine triphosphate, with oxygen and glucose being the main components involved. The imbalance in glucose levels in the central nervous system produces substantial changes in metabolism. Hypoglycemia, or decreased blood glucose levels below 50 mg/dl, is accompanied by symptoms such as decreased performance of cognitive tasks such as verbal fluency, reaction time, arithmetic ability, verbal memory and visual, in addition to excitotoxicity, oxidative stress, neuroinflammation and apoptosis. Hyperglycemia participates in some cardiovascular diseases, neuropathy, nephropathy, retinopathy. Changes in glucose metabolism must be regulated and considered in order to obtain the best treatment for different pathologies, such as infections, non-infections, traumatic, primary or acquired.

10 November 2022 in Archivos de Neurociencias
Verified
Journal Article
Open access
PDF file
DODANIEL San Juan Orta
DANIEL San Juan Orta
DPDaniel Arturo Martínez Piña
Daniel Arturo Martínez Piña
Introduction: Kambo is the skin secretion of the toxic Brazilian frog Phyllomedusa bicolor and has been practiced its inoculation through the human skin worldwide, especially in South America, by curiosity or to cure multiple diseases. Objective: Report a case of poisoning in a current ritual with Kambo frog poison.  Results: 41-year-old male, Marijuana user with a last consumption three months ago. He used Kambo for generalized anxiety disorder with panic attacks and claustrophobia. He suffered complications, including neuropathy, that we associate to the toxic effect of Kambo. He received oral prednisone, diphenidol and paroxetine as treatment with improvement. Discussión: The substances that can be related to the neuropathy are tachykinin through the B receptors that participate in mechanisms linked to pain, dermorphins and deltorphins, Mu opioid agonists that act on Mu and Delta receptors of the central nervous system involved in analgesic effects, exist two phases have been described in Kambo intoxication: the first phase (usually 15-30 minutes) and the second phase, that include the persistence of acute symptoms, syndrome of inappropriate antidiuretic hormone secretion, acute toxic hepatitis, and dermatomyositis. Our patient presented the classic acute symptoms, however, he had focal sensory neuropathy. Conclusion: Clinicians need to be aware of the complications of this shamanic ritual expanding worldwide.

6 November 2023
Verified
Journal Article
Open access
DMDaniel Arturo Martínez-Piña
Daniel Arturo Martínez-Piña
DODANIEL San Juan Orta
DANIEL San Juan Orta
EGEdith González-Guevara
Edith González-Guevara
CVClara Elena Vázquez-Díaz
Clara Elena Vázquez-Díaz
MHMartha A. Hernández-González
Martha A. Hernández-González
JSJosé Octavio Sosa-Ramos
José Octavio Sosa-Ramos
Existen condiciones neurológicas severas en pacientes con COVID-19, como: enfermedad cerebrovascular, síndrome de Guillain-Barré, encefalitis, encefalopatía necrotizante hemorrágica aguda y mielitis. describimos que el paciente con SARS-CoV-2 con síntomas respiratorios tiene manifestaciones neurológicas sutiles o subclínicas. estudio observacional, transversal, analítico, que incluyó pacientes de 18-65 años con síntomas respiratorios y diagnóstico de COVID-19 confirmado. Se excluyeron pacientes intubados, con enfermedades neurodegenerativas crónicas o compromiso neurológico preexistente. Se realizó semiología de la cefalea y exploración neurológica; Se midieron los niveles séricos de glucosa, proteínas, electrolitos, lactato, proteína C reactiva, deshidrogenasa láctica y dímero D. También se realizaron análisis de líquido cefalorraquídeo (LCR) y un electroencefalograma (EEG) en los pacientes que aceptaron los riesgos. se encontró alta prevalencia de manifestaciones neurológicas sutiles en pacientes con COVID-19 con solo cuadro clínico respiratorio. Cefalea, anosmia, disgeusia e hipopalestesia predominaron en las primeras etapas, con hallazgos anormales frecuentes en el LCR (>70%) y con menos frecuencia en el EEG (<20%). la cefalea, anosmia, disgeusia e hipoestesia fueron frecuentes al inicio de la infección, junto con hallazgos anormales en LCR y EEG, sin otros síntomas neurológicos ni enfermedad neurológica.